Grandfield & Dodd LLC Acquires New Holdings in Alnylam Pharmaceuticals, Inc. $ALNY

Grandfield & Dodd LLC bought a new stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) during the 2nd quarter, Holdings Channel.com reports. The fund bought 3,204 shares of the biopharmaceutical company’s stock, valued at approximately $964,000.

A number of other large investors have also added to or reduced their stakes in ALNY. MV Capital Management Inc. bought a new stake in shares of Alnylam Pharmaceuticals in the 4th quarter valued at about $25,000. Caitong International Asset Management Co. Ltd bought a new position in shares of Alnylam Pharmaceuticals during the 3rd quarter worth approximately $29,000. HM Payson & Co. bought a new position in shares of Alnylam Pharmaceuticals during the 4th quarter worth approximately $27,000. Golden State Wealth Management LLC lifted its position in Alnylam Pharmaceuticals by 100.0% during the fourth quarter. Golden State Wealth Management LLC now owns 72 shares of the biopharmaceutical company’s stock valued at $29,000 after acquiring an additional 36 shares during the last quarter. Finally, Manchester Capital Management LLC lifted its position in Alnylam Pharmaceuticals by 600.0% during the fourth quarter. Manchester Capital Management LLC now owns 84 shares of the biopharmaceutical company’s stock valued at $33,000 after acquiring an additional 72 shares during the last quarter. 92.97% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other Alnylam Pharmaceuticals news, Director David E. I. Pyott sold 3,830 shares of Alnylam Pharmaceuticals stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $299.18, for a total transaction of $1,145,859.40. Following the completion of the sale, the director owned 1,582 shares of the company’s stock, valued at approximately $473,302.76. The trade was a 70.77% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 0.86% of the company’s stock.

Analysts Set New Price Targets

Several research firms have issued reports on ALNY. Wells Fargo & Company cut their price target on shares of Alnylam Pharmaceuticals from $316.00 to $256.00 and set an “equal weight” rating on the stock in a report on Friday. Royal Bank Of Canada decreased their price objective on Alnylam Pharmaceuticals from $445.00 to $350.00 and set an “outperform” rating for the company in a report on Friday, July 31st. Sanford C. Bernstein upgraded Alnylam Pharmaceuticals to a “strong-buy” rating in a research note on Wednesday, July 29th. JPMorgan Chase & Co. reduced their target price on Alnylam Pharmaceuticals from $400.00 to $375.00 and set an “overweight” rating on the stock in a research report on Friday, July 31st. Finally, Needham & Company LLC decreased their price target on Alnylam Pharmaceuticals from $510.00 to $357.00 and set a “buy” rating for the company in a research note on Thursday, July 30th. Three investment analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and five have given a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $393.86.

Alnylam Pharmaceuticals Trading Down 1.8%

NASDAQ ALNY opened at $224.60 on Tuesday. The company has a fifty day simple moving average of $271.51 and a two-hundred day simple moving average of $300.10. The stock has a market cap of $30.05 billion, a P/E ratio of 41.75 and a beta of 0.30. Alnylam Pharmaceuticals, Inc. has a 12-month low of $197.81 and a 12-month high of $495.55. The company has a current ratio of 3.05, a quick ratio of 2.99 and a debt-to-equity ratio of 0.75.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $1.84 earnings per share for the quarter, beating analysts’ consensus estimates of $1.63 by $0.21. Alnylam Pharmaceuticals had a net margin of 15.26% and a return on equity of 84.93%. The firm had revenue of $1.29 billion for the quarter, compared to analyst estimates of $1.32 billion. During the same period in the previous year, the company earned ($0.51) earnings per share. The business’s quarterly revenue was up 66.9% compared to the same quarter last year. On average, analysts forecast that Alnylam Pharmaceuticals, Inc. will post 6.59 earnings per share for the current year.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.